Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Bioscience crawled date : 2021 - 11 - 30 save search
Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ENSC | $0.6795 22K
|
Health Technology
|
| O: 2.83%
H: 0.0%
C: 0.0%
trial opioid bioscience
Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
|
| O: -3.14%
H: 0.0%
C: 0.0%
fda clearance fda clearance bioscience
Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
EVFM | $0.015 280K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
fda bioscience
Twist Bioscience Announces Participation in SRC-SIA Webinar on the Decadal Plan for Semiconductors
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
TWST | $28.52 -7.04% 270K
|
Health Technology
|
| O: -2.43%
H: 0.0%
C: 0.0%
semiconductor bioscience
Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying Its Spatial Biology Technologies to Accelerating Precision Cancer Therapies
Published: 2021-11-30 (Crawled : 13:30) - globenewswire.com
AKYA | $4.02 0.25% 140K
|
Professional, Scientific, and T...
|
| O: 0.71%
H: 0.0%
C: 0.0%
bioscience cancer milestone therapy
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
Published: 2021-11-30 (Crawled : 13:00) - globenewswire.com
DRUG | $1.25 -6.61% 11K
|
Manufacturing
|
| O: -9.89%
H: 0.0%
C: 0.0%
disease treatment bioscience
IDEAYA Biosciences to Participate in Investor Conferences in December 2021
Published: 2021-11-30 (Crawled : 12:00) - biospace.com/
IDYA | $41.7 0.46% 160K
|
Health Technology
|
| O: -10.93%
H: 0.0%
C: 0.0%
bioscience conference
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
Published: 2021-11-30 (Crawled : 09:00) - biospace.com/
RCUS 4 | $16.57 1.72% 88K
|
Health Technology
|
| O: -3.85%
H: 0.0%
C: 0.0%
bioscience license arcus
Gainers vs Losers
| 51% | 49% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.